345 related articles for article (PubMed ID: 30606734)
1. Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.
Lleó A; Núñez-Llaves R; Alcolea D; Chiva C; Balateu-Paños D; Colom-Cadena M; Gomez-Giro G; Muñoz L; Querol-Vilaseca M; Pegueroles J; Rami L; Lladó A; Molinuevo JL; Tainta M; Clarimón J; Spires-Jones T; Blesa R; Fortea J; Martínez-Lage P; Sánchez-Valle R; Sabidó E; Bayés À; Belbin O
Mol Cell Proteomics; 2019 Mar; 18(3):546-560. PubMed ID: 30606734
[TBL] [Abstract][Full Text] [Related]
2. VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome.
Lleó A; Carmona-Iragui M; Videla L; Fernández S; Benejam B; Pegueroles J; Barroeta I; Altuna M; Valldeneu S; Xiao MF; Xu D; Núñez-Llaves R; Querol-Vilaseca M; Sirisi S; Bejanin A; Iulita MF; Clarimón J; Blesa R; Worley P; Alcolea D; Fortea J; Belbin O
Alzheimers Res Ther; 2021 Jun; 13(1):119. PubMed ID: 34183050
[TBL] [Abstract][Full Text] [Related]
3. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease.
Duits FH; Brinkmalm G; Teunissen CE; Brinkmalm A; Scheltens P; Van der Flier WM; Zetterberg H; Blennow K
Alzheimers Res Ther; 2018 Jan; 10(1):5. PubMed ID: 29370833
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer's disease continuum.
Goossens J; Cervantes González A; Dewit N; Lidón L; Fortea J; Alcolea D; Lleó A; Belbin O; Vanmechelen E
Alzheimers Res Ther; 2023 Oct; 15(1):186. PubMed ID: 37898760
[TBL] [Abstract][Full Text] [Related]
5. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
[TBL] [Abstract][Full Text] [Related]
6. Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry.
Camporesi E; Nilsson J; Vrillon A; Cognat E; Hourregue C; Zetterberg H; Blennow K; Becker B; Brinkmalm A; Paquet C; Brinkmalm G
EBioMedicine; 2022 Jan; 75():103793. PubMed ID: 34990894
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.
Visser PJ; Reus LM; Gobom J; Jansen I; Dicks E; van der Lee SJ; Tsolaki M; Verhey FRJ; Popp J; Martinez-Lage P; Vandenberghe R; Lleó A; Molinuevo JL; Engelborghs S; Freund-Levi Y; Froelich L; Sleegers K; Dobricic V; Lovestone S; Streffer J; Vos SJB; Bos I; ; Smit AB; Blennow K; Scheltens P; Teunissen CE; Bertram L; Zetterberg H; Tijms BM
Mol Neurodegener; 2022 Mar; 17(1):27. PubMed ID: 35346299
[TBL] [Abstract][Full Text] [Related]
8. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease.
Chatterjee M; Del Campo M; Morrema THJ; de Waal M; van der Flier WM; Hoozemans JJM; Teunissen CE
Alzheimers Res Ther; 2018 Jun; 10(1):52. PubMed ID: 29859129
[TBL] [Abstract][Full Text] [Related]
9. A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease.
Brinkmalm G; Sjödin S; Simonsen AH; Hasselbalch SG; Zetterberg H; Brinkmalm A; Blennow K
Proteomics Clin Appl; 2018 Jan; 12(1):. PubMed ID: 29028155
[TBL] [Abstract][Full Text] [Related]
10. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
[TBL] [Abstract][Full Text] [Related]
12. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome.
Belbin O; Xiao MF; Xu D; Carmona-Iragui M; Pegueroles J; Benejam B; Videla L; Fernández S; Barroeta I; Nuñez-Llaves R; Montal V; Vilaplana E; Altuna M; Clarimón J; Alcolea D; Blesa R; Lleó A; Worley PF; Fortea J
Mol Neurodegener; 2020 Aug; 15(1):46. PubMed ID: 32807227
[TBL] [Abstract][Full Text] [Related]
14. Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.
Wildsmith KR; Schauer SP; Smith AM; Arnott D; Zhu Y; Haznedar J; Kaur S; Mathews WR; Honigberg LA
Mol Neurodegener; 2014 Jun; 9():22. PubMed ID: 24902845
[TBL] [Abstract][Full Text] [Related]
15. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
Zhang H; Lyu D; Jia J;
J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042
[TBL] [Abstract][Full Text] [Related]
16. High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid.
Hendrickson RC; Lee AY; Song Q; Liaw A; Wiener M; Paweletz CP; Seeburger JL; Li J; Meng F; Deyanova EG; Mazur MT; Settlage RE; Zhao X; Southwick K; Du Y; Holder D; Sachs JR; Laterza OF; Dallob A; Chappell DL; Snyder K; Modur V; King E; Joachim C; Bondarenko AY; Shearman M; Soper KA; Smith AD; Potter WZ; Koblan KS; Sachs AB; Yates NA
PLoS One; 2015; 10(8):e0135365. PubMed ID: 26270474
[TBL] [Abstract][Full Text] [Related]
17. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia.
Das S; Goossens J; Jacobs D; Dewit N; Pijnenburg YAL; In 't Veld SGJG; Teunissen CE; Vanmechelen E
Alzheimers Res Ther; 2023 Mar; 15(1):62. PubMed ID: 36964594
[TBL] [Abstract][Full Text] [Related]
18. Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum.
Paciotti S; Wojdała AL; Bellomo G; Toja A; Chipi E; Piersma SR; Pham TV; Gaetani L; Jimenez CR; Parnetti L; Chiasserini D
Alzheimers Res Ther; 2023 Jul; 15(1):124. PubMed ID: 37454217
[TBL] [Abstract][Full Text] [Related]
19. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum.
Milà-Alomà M; Salvadó G; Gispert JD; Vilor-Tejedor N; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; Arenaza-Urquijo EM; Crous-Bou M; González-de-Echávarri JM; Minguillon C; Fauria K; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Suárez-Calvet M; Molinuevo JL;
Alzheimers Dement; 2020 Oct; 16(10):1358-1371. PubMed ID: 32573951
[TBL] [Abstract][Full Text] [Related]
20. Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.
Jahn H; Wittke S; Zürbig P; Raedler TJ; Arlt S; Kellmann M; Mullen W; Eichenlaub M; Mischak H; Wiedemann K
PLoS One; 2011; 6(10):e26540. PubMed ID: 22046305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
